Discovery, design, and optimization of isoxazole azepine BET inhibitors

ACS Medicinal Chemistry Letters

Volumn 4, Issue 9, 2013, Pages 835-840

  Gehling, Victor S ^a   Hewitt, Michael C ^a   Vaswani, Rishi G ^a   Leblanc, Yves ^a   Coîté, Alexandre ^a   Nasveschuk, Christopher G ^a   Taylor, Alexander M ^a   Harmange, Jean Christophe ^a   Audia, James E ^a   Pardo, Eneida ^a   Joshi, Shivangi ^a   Sandy, Peter ^a   Mertz, Jennifer A ^a   Sims, Robert J ^a   Bergeron, Louise ^a   Bryant, Barbara M ^a   Bellon, Steve ^a   Poy, Florence ^a   Jayaram, Hariharan ^a   Sankaranarayanan, Ravichandran ^b   Yellapantula, Sreegouri ^b   Bangalore Srinivasamurthy, Nandana ^b   Birudukota, Swarnakumari ^b   Albrecht, Brian K ^a   more..

^a Department of Structural Biology   (United States)

^b JUBILANT BIOSYS LTD   (India)

Author keywords

BET inhibitors; bromodomain; fragments; isoxazoles; MYC

Indexed keywords

AZEPINE DERIVATIVE; ISOXAZOLE DERIVATIVE; MOLECULAR SCAFFOLD;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT;

EID: 84884238437     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4001485     Document Type: Article

References (25)

1. Wu, S. Y.; Chiang, C. M. The Double Bromodomain-Containing Chromatin Adaptor Brd4 and Transcriptional Regulation J. Biol. Chem. 2007, 282, 13141-13145
2. Miyoshi, M.; Ooike, S.; Iwata, K.; Hikawa, H.; Sugahara, K. Antitumor Compounds, WO 2009/084693A1, 9 Sept 2009.
3. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective Inhibition of BET Bromodomains Nature 2010, 468, 1067-1073
4. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C. W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of Inflammation by a Synthetic Histone Mimic Nature 2010, 468, 1119-1123
5. Vita, M.; Henricksson, M.; Myc, M. M. Oncoprotein As a Therapeutic Target for Human Cancer Semin. Cancer Biol. 2006, 16, 318-330
6. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET Bromodomain Inhibition As a Therapeutic Strategy to Target c-Myc Cell 2011, 146, 904-917
7. Mertz, J. A.; Conery, A. R.; Bryant, B. M.; Sandy, P.; Balasubramanian, S.; Mele, D. A.; Bergeron, L.; Sims, R. J.; Targeting, M. Y. C. Dependence in Cancer by Inhibiting BET Bromodomains Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 16669-16674
8. Hewings, D. S.; Rooney, T. P. C.; Jennings, L. E.; Hay, D. A.; Schofield, C. J.; Brennan, P. E.; Knapp, S.; Conway, S. J. Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain-Acetyl-Lysine Interactions J. Med. Chem. 2012, 55, 9393-9413
9. Hay, D.; Fedorov, O.; Filippakopoulos, P.; Martin, S.; Philpott, M.; Picaud, S.; Hewings, D. S.; Uttakar, S.; Heightman, T. D.; Conway, S. J.; Knapp, S.; Brennan, P. E. The Design and Synthesis of 5- and 6-Isoxazoylbenzimidazoles As Selective Inhibitors of the BET Bromodomains Med. Chem. Commun. 2013, 4, 140-144
10. Hewings, D. S.; Wang, M.; Philpott, M.; Federov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Vuppusetty, C.; Marsden, B.; Knapp, S.; Conway, S. J.; Heightman, T. 3,5-Dimethylisoxazoles Act As Acetyl-Lysine-Mimetic Bromodomain Ligands J. Med. Chem. 2011, 54, 6761-6770
11. Hewings, D. S.; Federov, O.; Filippakopoulos, P.; Martin, S.; Picaud, S.; Tumber, A.; Wells, C.; Olcina, M. M.; Freeman, C.; Gill, A.; Ritchie, A. J.; Sheppard, D. W.; Russell, A. J.; Hammond, E. M.; Knapp, S.; Brennan, P. E.; Conway, S. J. Optimization of 3,5-Dimethylisoxazole Derivatives As Potent BET Bromodomain Ligands J. Med. Chem. 2013, 56, 3217-3227
12. Dawson, M. A.; Prinjha, R. K.; Dittman, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W. I.; Robson, S. C.; Chung, C. W.; Hopf, C.; Savitski, M. M.; Huthmacher, C.; Gudgin, E.; Lugo, D.; Beinke, S.; Chapman, T. D.; Roberts, E. J.; Soden, P. E.; Auger, K. R.; Mirguet, O.; Doehner, K.; Delwel, R.; Burnett, A. K.; Jeffrey, P.; Drewes, P.; Lee, K.; Huntly, B. J. P.; Kouzarides, T. Inhibition of BET Recruitment to Chromatin As an Effective Treatment for MLL-Fusion Leukemia Nature 2011, 478, 529-533
13. Lamotte, Y.; Donche, F.; Bouillot, A.; Mirguet, O.; Gellibert, F.; Nicodeme, E.; Krysa, G.; Kirilovsky, J.; Beinke, S.; McCleary, S.; Rioja, I.; Bamborough, P.; Chung, C. W.; Gordon, L.; Lewis, T.; Walker, A. L.; Cutler, L.; Lugo, D.; Wilson, D. M.; Witherington, J.; Lee, K.; Prinjha, R. K.; Seal, J. Identification of a Novel Series of BET Family Bromodomain Inhibitors: Binding Mode and Profile of I-BET151 (GSK1210151A) Bioorg. Med. Chem. Lett. 2012, 22, 2968-2972
14. Mirquet, O.; Lamotte, Y.; Donche, F.; Toum, J.; Gellibert, F.; Bouillot, A.; Gosmini, R.; Nguyen, V. L.; Delannee, D.; Seal, J.; Blandel, F.; Boullay, A. B.; Boursier, E.; Martin, S.; Brusq, J. M.; Krysa, G.; Riou, A.; Tellier, R.; Costaz, A.; Huet, P.; Dudit, Y.; Trottet, L.; Kirilovsky, J.; Nicodeme, E. From ApoA1 Upregulation to BET Family Bromodomain Inhibition: Discovery of I-BET151 Bioorg. Med. Chem. Lett. 2012, 22, 2963-2967
15. Chung, C. W.; Dean, A. W.; Woolven, J. M.; Bamborough, P. Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead Discovery J. Med. Chem. 2012, 55, 576-586
16. Bamborough, P.; Diallo, H.; Goodacre, J. D.; Gordon, L.; Lewis, A.; Seal, J. T.; Wilson, D. M.; Woodrow, M. D.; Chung, C. W. Fragment-Based Discovery of Bromodomain Inhibitors Part 2: Optimization of Phenylisoxazole Sulfonamides J. Med. Chem. 2012, 55, 587-596
17. Chung, C. W.; Herve, C.; White, J. H.; Olivier, M.; Wilde, J.; Gosmini, R. L.; Delves, C.; Magny, S. M.; Woodward, R.; Hughes, S. A.; Boursier, E. V.; Flynn, H.; Bouillot, A. M.; Bamborough, P.; Brusq, J.-M. G.; Gellibert, F. J.; Jones, E. J.; Riou, A. M.; Homes, P.; Martin, S. L.; Uings, I. J.; Toum, J.; Clement, C. A.; Boullay, A.-B.; Grimley, R. L.; Blandel, F. M.; Prinjha, R. K.; Lee, K.; Kirilovsky, J.; Nicodeme, E. Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains J. Med. Chem. 2011, 54, 3827-3838
18. Filippakopoulos, P.; Picaud, S.; Fedorov, O.; Keller, M.; Wrobel, M.; Morgenstern, O.; Bracher, F.; Knapp, S. Benzodiazepines and Benzotriazepines As Protein Interaction Inhibitors Targeting Bromodomains of the BET Family Bioorg. Med. Chem. 2012, 20, 1878-1886
19. Fish, P. V.; Filippakopoulos, P.; Bish, G.; Brennan, P. E.; Bunnage, M. E.; Cook, A. S.; Federov, O.; Gerstenberger, B. S.; Jones, H.; Knapp, S.; Marsden, B. B.; Nocka, K. K.; Owen, D. R.; Philpott, M. M.; Picaud, S. S.; Primiano, M. J.; Ralph, M. J.; Sciammetta, N. N.; Trzupek, J. D. Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit J. Med. Chem. 2012, 55, 9831-9837
20. Zhao, L.; Cao, D.; Chen, T.; Wang, Y.; Miao, Z.; Xu, Y.; Chen, W.; Wang, X.; Li, Y.; Du, Z.; Xiong, B.; Li, J.; Xu, C.; Zhang, N.; He, J.; Shen, J. Fragment-Based Drug Discovery of 2-Thiazolidinones As Inhibitors of the Histone Reader BRD4 Bromodomain J. Med. Chem. 2013, 56, 3833-3851
21. Perola, E. An Analysis of the Binding Efficiencies of Drugs and Their Leads in Successful Drug Discovery Programs J. Med. Chem. 2010, 53, 2986-2997
22. Abad-Zapatero, C. Ligand Efficiency Indices for Effective Drug Discovery Expert Opin. Drug Discovery 2007, 2, 469-488
23. Bembenek, S. D.; Tounge, B. A.; Reynolds, C. H. Ligand Efficiency and Fragment-Based Drug Discovery Drug Discovery Today 2009, 14, 278-283
24. May, P. C.; Dean, R. A.; Lowe, S. L.; Martenyl, F.; Sheehan, S. M.; Boggs, L. N.; Monk, S. A.; Mathes, B. M.; Mergott, D. J.; Watson, B. M.; Stout, S. L.; Timm, D. E.; LaBell, E. S.; Gonzales, C. R.; Nakano, M.; Jhee, S. S.; Yen, M.; Ereshefsky, L.; Lindstrom, T. D.; Calligaro, D. O.; Cocke, P. J.; Hall, D. G.; Friedrich, S.; Citron, M.; Audia, J. E. Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor J. Neurosci. 2011, 31, 16507-16516
25. Ellman, J. A.; Owens, T. D.; Tang, T. P. N-tert -Butanesulfinyl Imines: Versatile Intermediates for the Asymmetric Synthesis of Amines Acc. Chem. Res. 2002, 35, 984-995